Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma
Source: CureToday, November 2024
Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.
Among patients with resected stage 3 or 4 melanoma, treatment with immune-oncology agents such as Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated higher cure rates compared with those treated with a placebo.
According to study findings published in Journal of Oncology, “the analysis demonstrated that patients receiving [Opdivo] are more likely to be cured than those receiving [Yervoy] and those receiving [Yervoy] are more likely to be cured than those receiving [a] placebo,” study authors wrote.